Accretion Pharmaceuticals Limited

# Announcement

**Outcome of the Board Meeting**
**Board Meeting- Audited Financial Results for the half year and year ended March 31, 2025, and other agendas.**

Time of Commencement of Meeting: 5:00 P.M.

The Board of Directors of the Company have considered and approved the following agendas of the meeting as under:

1. As per the recommendation of Nomination and Remuneration Committee, the Board has appointed Ms. Nishtha Harivanshi Pamnani (DIN: 10881910) as an Additional Director (Non-Executive - Professional - Independent) of the Company for a period of 5 Years effective from June 10, 2025. Attached Annexure for details of new Director.

2. Approved the payment of sitting fees to Ms. Nishtha Harivanshi Pamnani (DIN: 10881910) Additional Director (Non-Executive - Professional - Independent) for attending board and committee meetings.

3. The Company took note of Resignation of Mr. Vijay Bharatbhai Anadkat (DIN: 09578670) as Independent Director of the company w.e.f. 26/05/2025.

4. The Board of Directors of the Company at their meeting held today has, inter-alia considered and approved the Audited Standalone Financial results of the Company for the half year and year ended March 31, 2025, of the Company. The Audited Financial Results of the Company are posted on the Company's website.

5. Approved the re-constitution of Audit Committee upon resignation of Mr. Vijay Bharatbhai Anadkat (DIN: 09578670)

6. Approved the re-constitution of Nomination and Remuneration Committee upon resignation of Mr. Vijay Bharatbhai Anadkat (DIN: 09578670)

7. Approved the re-constitution of Stakeholders Relationship Committee upon resignation of Mr. Vijay Bharatbhai Anadkat (DIN: 09578670)

8. Approved the reconstitution of Corporate Social Responsibility Committee upon resignation of Mr. Vijay Bharatbhai Anadkat (DIN: 09578670)

Time of Conclusion of Meeting: 5:30 P.M.

Thanking You,

BHAVIKA DHAVAL MAKADIA

Digitally signed by BHAVIKA DHAVAL MAKADIA
Date: 2025.06.10 17:54:23 +05'30'

Bhavika Dhaval Makadia
Company Secretary and compliance officer
Membership No.: A65190

Date: 10-06-2025

29, Xcelon Industrial park-1, Behind Intas Pharmaceuticals, Vasna-Chacharwadi, Ta-Sanand, Dist-Ahmedabad
382 213, Gujarat, INDIA Mobile: +919723755277 9624381960 9723935999
Email: info@accretionpharma.com, Website: www.accretionpharma.com
CIN: U21004GJ2023PLC146545

## Annexure

**Details as required under SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023**

**Ms. Nishtha Harivanshi Pamnani**

| Sl. No. | Details of events that need to be provided | Information of such event(s) |
|---|---|---|
| 1 | Reason for change viz. appointment, ~~resignation, removal, death or otherwise~~ | Ms. Nishtha Harivanshi Pamnani is appointed as an Additional Director (Non-Executive – Professional - Independent) with effect from June 10, 2025, subject to shareholders' approval. |
| 2 | Date of Re-appointment & Term of Appointment | Ms. Nishtha Harivanshi Pamnani is appointed as an Additional Director (Non-Executive – Professional - Independent) with effect from June 10, 2025.<br><br>Terms of Appointment: For the period of five years from the date of appointment subject to shareholders' approval. |
| 3 | Brief Profile | Mrs. Nishtha Harivanshi Pamnani is a qualified Company Secretary. She holds an MBA in Finance from Sikkim Manipal University and a BBA from Biyani Girls College, affiliated with the University of Rajasthan, providing her with a strong academic foundation in business and finance.<br><br>With over 8 years of extensive experience in corporate governance, legal compliance, securities laws, and regulatory frameworks, she has served as Company Secretary and Compliance Officer in both listed and private companies across diverse sectors, including textiles, construction, and aquaculture. She brings in-depth expertise in secretarial practices, SEBI regulations, corporate law, and board governance, along with practical knowledge of finance and accounting functions. Her well-rounded experience and governance-first approach make her well-suited for Independent Director roles, contributing effectively to strategic oversight and ethical corporate management. |
| 4 | Disclosure of relationships between directors (in case of appointment of a director) | Ms. Nishtha Harivanshi Pamnani is not related to any of the Directors or Key Managerial Personnel or Promoters and Promoter group of the Company. |
| 5 | Information as required under BSE circular no. LIST/COMP/14/2018-19, dated June 20, 2018. | Ms. Nishtha Harivanshi Pamnani is not debarred from holding the office of Director by any SEBI order or any other such authority |

BHAVIKA DHAVAL MAKADIA

Digitally signed by BHAVIKA DHAVAL MAKADIA
Date: 2025.06.10 17:54:40 +05'30'

VSSB & ASSOCIATES
CHARTERED ACCOUNTANTS

# INDEPENDENT AUDITOR'S REPORT

**Independent Auditor's Report on Standalone Half Yealy Financial Results and year to date result of Accretion Pharmaceuticals Limited ("the Company") pursuant to the requirements of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, as amended.**

**TO THE BOARD OF DIRECTORS of ACCRETION PHARMACEUTICALS LIMITED**

**Opinion**

We have audited the accompanying statement of half yearly and year to date standalone financial results of Accretion Pharmaceuticals Limited (hereinafter referred to as the "Company") for the year ended 31 March 2025, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (" The Listing Regulations").

In our opinion, to the best of our information, according to the explanations given to us, the aforesaid Standalone Financial Results for the year ended 31st March 2025:

a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable in the applicable Accounting Standards Prescribed under section 133 of the Companies Act, 2013 ("Act"), as amended, and other accounting principles generally accepted in India under of the net profit and other financial information for the year ended 31 March 2025.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial results for the year ended 31st March 2025 under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

V S B & ASSOCIATES CHARTERED ACCOUNTANTS FRN 121356W PARTNER

**HEAD OFFICE:** A/912, 9th Floor, Ratnaakar Nine Square, Opp. ITC Narmada Hotel, Vastrapur, Ahmedabad – 380015, GJ
(o) 079 2754 1783 (m) +91 93777 71182 (e) cavishves@gmail.com / cashridhar@gmail.com

**Responsibilities of the Management and Those Charged with Governance for this Statement:**

This accompanying Statement, which includes the Standalone Financial Results for the year ended 31st March 2025 is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. This responsibility includes the preparation and presentation of the Standalone Financial Results for the half yearly and year ended 31st March, 2025 that give a true and fair view of the net profit and other financial information in accordance with the recognition and measurement principles laid down in the applicable Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulations 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the accompanying Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

**Auditor's Responsibilities for the Audit of the Standalone Financial Results for the year ended 31st March, 2025:**

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended 31st March 2025 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Annual Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We are also:

- Identify and assess the risks of material misstatement of the Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone Financial Results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the standalone financial results of the company to express an opinion on the standalone financial results.

Materiality is the magnitude of misstatements in the Standalone financial results that, individually or in aggregate, makes it probable that economic decisions of a reasonably knowledgeable users of the standalone financial results may be influenced. We consider Quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



**Other Matter**

1. Company is listed on NSE Emerge (SME) stock exchange as on 21/05/2025, and this is the first Financial Result of the Company.
2. The accompanying Statement includes the results for the half year ended 31st March, 2025 being the balancing figure between audited figures in respect of the full financial year and year to date figures up to the half year of the current financial year. Our opinion on the Audit of the Standalone Financial Results for the year ended 31st March 2025 is not modified in respect of this matter.

Date 10/06/2025
Place Ahmedabad

**For, V S S B & Associates**
Chartered Accountants.
Firm Reg. No.121356W

V S S B & ASSOCIATES * CHARTERED ACCOUNTANTS * FRN 121356W PARTNER

Vishves A. Shah
(Partner)
Membership No. 109944
UDIN: 25109944BMGPMN6301

**ACCRETION PHARMACEUTICALS LIMITED**

(CIN: U21004GJ2023PLC146545)

**Regd. Office :-** 29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213

**Audited Statement of Standalone Financial Result for the half year ended March 31, 2025**

(Amount in Lakhs)

| | Particulars | Half Year Ended | | | Year Ended | |
|---|---|---|---|---|---|---|
| | | 31-03-2025 | 30-09-2024 | 31-03-2024 | 31-03-2025 | 31-03-2024 |
| | | (Audited) | (Unaudited) | (Audited) *(See Note 4)* | (Audited) | (Audited) *(See Note 4)* |
| I | Revenue from Operations | 3881.20 | 1856.42 | 1335.25 | 5737.62 | 1335.25 |
| II | Other Income | 7.91 | 1.53 | 5.47 | 9.44 | 5.47 |
| III | **Total Income (I + II)** | **3889.11** | **1857.95** | **1340.71** | **5747.06** | **1340.71** |
| IV | **Expenses** | | | | | |
| | Cost of Material Consumed | 2921.91 | 1449.10 | 1516.78 | 4371.01 | 1516.78 |
| | Purchases | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | Changes in inventories of finished goods, work-in-progress and stock-in-trade | (129.06) | (250.98) | (580.19) | (380.04) | (580.19) |
| | Employee Benefits Expenses | 213.49 | 154.00 | 90.08 | 367.49 | 90.08 |
| | Finance Costs | 74.27 | 69.42 | 39.92 | 143.69 | 39.92 |
| | Depreciation and Amortization Expense | 40.75 | 36.70 | 22.35 | 77.45 | 22.35 |
| | Other Expenses | 120.73 | 70.35 | 52.27 | 191.08 | 52.27 |
| | **Total Expense** | **3242.09** | **1528.59** | **1141.21** | **4770.68** | **1141.21** |
| V | **Profit before Exceptional and Extraordinary Items and Tax (III-IV)** | **647.02** | **329.36** | **199.50** | **976.38** | **199.50** |
| VI | Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| VII | **Profit before Extraordinary Items and Tax (V-VI)** | **647.02** | **329.36** | **199.50** | **976.38** | **199.50** |
| VIII | Extraordinary Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| IX | **Profit Before Tax (VII-VIII)** | **647.02** | **329.36** | **199.50** | **976.38** | **199.50** |
| X | **Tax Expense:** | | | | | |
| | (a) Current Tax | 177.04 | 82.89 | 50.08 | 259.93 | 50.08 |
| | (b) Deferred Tax | 19.32 | 0.00 | 0.14 | 19.32 | 0.14 |
| | (c) MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | (d) Income Tax of Previous Year | 17.78 | 0.00 | 0.00 | 17.78 | 0.00 |
| | **Total Tax Expense** | **214.14** | **82.89** | **50.21** | **297.03** | **50.21** |
| XI | **Profit for the Period from Continuing Operations (IX - X)** | **432.89** | **246.47** | **149.29** | **679.35** | **149.29** |
| XII | Profit/(Loss) for the Period from Discontinuing Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| XIII | Tax Expense of Discontinuing Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| XIV | **Profit/(Loss) from Discontinuing Operations (After Tax) (XII-XIII)** | **0.00** | **0.00** | **0.00** | **0.00** | **0.00** |
| XV | **Profit for the Period (XI + XIV)** | **432.89** | **246.47** | **149.29** | **679.35** | **149.29** |
| XVI | Paid up Share Capital (Face Value Rs. 10/Share) | 817.00 | 817.00 | 400.00 | 817.00 | 400.00 |
| XVII | Reserve excluding Revaluation Reserves | - | - | - | 711.65 | 149.29 |
| XVIII | **Earnings Per Equity Share:** | | | | | |
| | Basic (Rs.) & Diluted (Rs.) *(See Note 8)* | 5.30 | 3.14 | 1.96 | 8.48 | 1.96 |

**Notes:**

1. The above Audited financial results were reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on **10/06/2025**.
2. The previous periods figures have been regrouped whereever necessary.
3. The Statutory auditors of the company have carried out an Audit and issued "Independent Auditor's report" of the above results as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.
4. The Company has been incorporated as on 29th November, 2023 by conversion of Partnership Firm. Hence, Previous year's Audited figures of the Company consist of period between 29/11/2023 to 31/03/2024.
5. The Company is mainly engaged in the business of manufacture, process, trade, sale, purchase, import, export, assemble, distribute, formulate, develop, consult, test and deal in all kind of Drugs, Pharmaceuticals products and related products thereto and which is considered as only reportable primary business segment as per Accounting Standard "Segment Reporting" (AS - 17). As such, no separate disclosure for Segment Reporting is made.
6. The figures for the half year ended 31st March, 2025 are the balancing figures between the audited figures in respect of full financial year and the year-to-date figures up to the first half year of the financial year.
7. The company had made an intial public offering (IPO) of 29,46,000 equity shares of face value of Rs. 10 each fully paid up for cash at a price of Rs. 101 per equity shares (including share premium of Rs. 91 per equity share) aggregating to Rs. 29,75,46,000/- The equity shares of the company got listed on NSE Emerge Platform on 21st May, 2025.
8. Earning per share is not retrospectively effected due to Fresh issue of equity as it is considered as Non-Adjusting event as per AS 4 'Contingencies and Events Occurring After the Balance Sheet Date'.

ACCRETION PHARMACEUTICALS LIMITED AHMEDABAD

**For and on Behalf of the Board of,**
**ACCRETION PHARMACEUTICALS LIMITED**

Vivek Ashok Kumar Patel
**(Managing Director)**
DIN: 09130357

Place: Ahmedabad
Date : 10/06/2025

# ACCRETION PHARMACEUTICALS LIMITED

(CIN: U21004GJ2023PLC146545)

Regd. Office :- 29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213

Audited Statement of Assets & Liabilities as at 31st March, 2025

(Amount in Lakhs)

| | Particulars | Audited AS AT 31.03.2025 | Audited AS AT 31.03.2024 |
|---|---|---|---|
| I | **Equity & Liabilities** | | |
| | **1. Shareholders' funds** | | |
| | (a) Share Capital | 817.00 | 400.00 |
| | (b) Reserves and Surplus | 711.65 | 149.29 |
| | (c) Money received against share warrants | 0.00 | 0.00 |
| | | | |
| | 2. Share application money pending allotment | 0.00 | 0.00 |
| | | | |
| | | **1528.65** | **549.29** |
| | **3. Non - Current Liabilities** | | |
| | (a) Long -Term Borrowings | 116.76 | 691.07 |
| | (b) Deferred Tax Liabilities (Net) | 19.45 | 0.14 |
| | (c) Other Long - Term Liabilities | 0.00 | 0.00 |
| | (d) Long - Term Provisions | 0.00 | 0.00 |
| | | | |
| | **4. Current Liabilities** | | |
| | (a) Short - Term Borrowings | 1293.58 | 656.71 |
| | (b) Trade Payables | | |
| | Micro and Small Enterprises | 183.90 | 163.95 |
| | Other than Micro and Small Enterprises | 574.72 | 493.80 |
| | (c) Other Current Liabilities | 4.47 | 3.00 |
| | (d) Short - Term Provisions | 265.90 | 128.95 |
| | | | |
| | | **2458.79** | **2137.61** |
| | Total | **3987.44** | **2686.90** |
| II | **Assets** | | |
| | **1. Non - Current Assets** | | |
| | (a) Property, Plant & Equipment & Intangible Assets | | |
| | (i) Property, Plant & Equipment | 609.09 | 525.46 |
| | (ii) Intangible Assets | 0.00 | 0.00 |
| | (iii) Capital Work-in-Progress | 0.00 | 0.00 |
| | (iv) Intangible Assets under Development | 0.00 | 0.00 |
| | (b) Non - Current Investments | 0.00 | 0.00 |
| | (c) Long - Term Loans and Advances | 7.56 | 0.00 |
| | (d) Other Non - Current Assets | 16.08 | 13.38 |
| | (d) Deferred Tax Assets (Net) | 0.00 | 0.00 |
| | | **632.73** | **538.85** |
| | **2. Current Assets** | | |
| | (a) Inventories | 2060.97 | 1447.58 |
| | (b) Trade Receivables | 1166.11 | 580.44 |
| | (c) Cash and Cash equivalents | 5.08 | 9.16 |
| | (d) Short - Term Loans and Advances | 110.36 | 105.42 |
| | (e) Other Current Assets | 12.18 | 5.45 |
| | | **3354.71** | **2148.06** |
| | Total | **3987.44** | **2686.90** |

Place : Ahmedabad
Date : 10/06/2025

ACCRETION PHARMACEUTICALS LIMITED AHMEDABAD

For & on behalf of the Board,
ACCRETION PHARMACEUTICALS LIMITED

Vivek Ashok Kumar Patel
**(Managing Director)**
DIN : 09130357

## ACCRETION PHARMACEUTICALS LIMITED

(CIN: U21004GJ2023PLC146545 )

**Regd. Office :-** 29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213

### AUDITED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED MARCH 31, 2025

(Amount in Lakhs)

| Particulars | Period ended 31th March, 2025 Rs. | | Year ended 31st March, 2024 Rs. | |
|---|---|---|---|---|
| **CASH FLOW FROM OPERATING ACTIVITIES** | | | | |
| Net Profit before Tax for the year | | 976.38 | | 199.50 |
| **Adjustments for :** | | | | |
| Transferred from reserve | 0.00 | | 0.00 | |
| Interest Expense | 143.69 | | 39.92 | |
| Depreciation | 77.45 | | 22.35 | |
| | | 221.14 | | 62.26 |
| **Operating Profit before Working Capital change** | | 1197.53 | | 261.76 |
| **Adjustments for :** | | | | |
| Decrease/(Increase) in Receivables | (585.67) | | (704.69) | |
| Decrease/(Increase) in Inventories | (613.38) | | (1447.58) | |
| Decrease/(Increase) in Short Term Loans & Advances | (4.95) | | 0.00 | |
| Decrease/(Increase) in Other Current Assets | (6.73) | | 0.00 | |
| Increase/(Decrease) in Short Term Borrowing | 636.87 | | 0.00 | |
| Increase/(Decrease) in Payables | 100.87 | | 660.75 | |
| Increase/(Decrease) in Current Liabilities | 1.47 | | 0.00 | |
| Other Non Current Asset | (2.70) | | 0.00 | |
| Increase/(Decrease) in Provisions | 45.01 | (429.21) | 0.00 | (1491.52) |
| **Cash Generated From Operations** | | 768.32 | | (1229.76) |
| Income Tax | | 185.77 | | 78.87 |
| **NET CASH FROM OPERATING ACTIVITIES Total (A)** | | 582.55 | | (1150.89) |
| **CASH FLOW FROM INVESTING ACTIVITIES** | | | | |
| Non Current Investment | | | 0.00 | |
| Purchase Of Fixed Asset | (161.08) | | (547.81) | |
| **NET CASH USED IN INVESTING ACTIVITIES Total (B)** | | (161.08) | | (547.81) |
| **CASH FLOW FROM FINANCING ACTIVITIES** | | | | |
| Long Term Borrowing | (574.31) | | 1347.78 | |
| Proceeds from share issued including share application money | 300.00 | | 400.00 | |
| Long Term Loans & Advances | (7.56) | | 0.00 | |
| Interest Expenses | (143.69) | | (39.92) | |
| **NET CASH FROM FINANCING ACTIVITIES Total (C)** | | (425.56) | | 1707.86 |
| Net Increase/(Decrease) in Cash and Cash Equivalents Total (A+B+C) | | (4.08) | | 9.16 |
| Cash and Cash Equivalents -- Opening Balance | | 9.16 | | 0.00 |
| Cash and Cash Equivalents -- Closing Balance | | 5.08 | | 9.16 |
| | | 0.00 | | 0.00 |
| **Note: Previous year's figures have been regrouped/rearranged wherever considered necessary.** | | | | |

Place : Ahmedabad
Date : 10/06/2025

**For & on behalf of the Board,**
**ACCRETION PHARMACEUTICALS LIMITED**

ACCRETION PHARMACEUTICALS LIMITED AHMEDABAD

Vivek Ashok Kumar Patel
**(Managing Director)**
DIN: 09130357